Cancer Institute A national cancer institute
designated cancer center

Tumor Heterogeneity: Implications for Targeted Therapy

October 6 - 7, 2014
Li Ka Shing Center for Learning & Knowledge

Sponsored by the Stanford Cancer Institute

Monday, October 6 : Morning Session

7:15 - Registration & Breakfast

8:00 - Welcome

Beverly Mitchell, Professor of Medicine, Director, Stanford Cancer Institute

8:10 - Overview

Ron Levy, Professor of Medicine, Assoc. Director for Translational Research, Stanford Cancer Institute

8:30 - Keynote   

Breast Tumor Heterogeneity
Kornelia Polyak, Professor, Department of Medicine, Harvard Medical School

9:30 - Break

9:45 - Panel        

How precisely can we measure and interpretintra-patient tumor heterogeneity?                   

  • David Haussler, Distinguished Professor of Biomolecular Engineering, University of California, Santa Cruz
  • Gary Nolan, Professor of Microbiology and Immunology, Stanford University
  • Stephen Quake, Professor of Bioengineering, Stanford University
  • Carlo Maley (moderator),Assoc. Professor, Department of Surgery, Director, Center for Evolution and Cancer, University of California, San Francisco

11:45 - Lunch

12:15 - Lunch Address

Normal and Neoplastic Stem Cells.
Irving Weissman, Professor of Developmental Biology, Director Stanford Institute for Stem Cell Biology and Regenerative Medicine

Tuesday, October 7 : Morning Session

8:00 - Breakfast

8:30 - Keynote

Can An Evolutionary and Ecological Perspective Bring New Insights into the Heterogeneity Issue?
Carlo Maley, Assoc. Professor, Department of Surgery, Director, Center for Evolution and Cancer, University of California, San Francisco.

9:30 - Panel          

Are immune therapies superior to other targeted therapies in treating heterogeneous tumors?

  • Ron Levy, Professor of Medicine, Assoc. Director for Translational Research, Stanford Cancer Institute
  • Ash Alizadeh, Assistant Professor of Medicine, Stanford University
  • Paul Robbins (moderator), Staff Scientist, National Cancer Institute

11:00 - Break

11:15 - Keynote   

Spatial and Temporal Heterogeneity in Solid Tumors:Implications for Trial Design 
Charles Swanton, Professor, Cancer Research UK, London Research Institute

12:15 - Lunch & Poster Session

Monday, October 6 : Afternoon Session

1:15 - Keynote   

Understanding the Cancer Genome
Kenneth Kinzler, Professor of Oncology, Johns Hopkins University

2:15 - Break

2:30 - Panel 

How will transcriptomic, microenvironmental andproteomic heterogeneity affect therapeutic strategies?

  • Megan Hitchins, Assoc. Professor of Medicine, Stanford University
  • Mina Bissell, Distinguished Scientist, Lawrence Berkeley National Laboratory
  • Kimberly Allison, Assoc. Professor of Pathology, Stanford University
  • Kornelia Polyak (moderator), Professor, Department of Medicine, Harvard Medical School

4:00 - Short Talk

How should concerns about heterogeneity affect current and future clinical practice?
George Sledge, Professor of Medicine, Stanford University

4:30 - Reception & Informal Poster Viewing

 

Tuesday, October 7 : Afternoon Session

1:15 - Panel        

How should intra-patient heterogeneity affect thedesign of clinical trials?

  • Mark Pegram, Professor of Medicine, Assoc. Director for Clinical Research, Stanford Cancer Institute
  • Joel Neal, Assistant Professor of Medicine, Stanford University
  • Charles Swanton (moderator), Professor, Cancer Research UK, London Research Institute

2:45 - Break

3:00 - Panel                    

Implications of intra-patient heterogeneity fordiagnostics, treatment, and monitoring response.

  • Andrei Iagaru, Assistant Professor of Radiology, Stanford University
  • Matt van de Rijn, Professor of Pathology, Stanford University
  • Maximillian Diehn, Assistant Professor of Medicine, Stanford University
  • R. West (moderator), Associate Professor of Pathology, Stanford University

4:30 - Wrap-up

What Have We Learned? What Do We Need to Learn?

  • Beverly Mitchell, Professor of Medicine, Director, Stanford Cancer Institute
  • Ron Levy, Professor of Medicine, Assoc. Director for Translational Research, Stanford Cancer Institute
  • Daniel Kapp, Professor Emeritus, Radiation Oncology, Stanford University

 

 

 

 

 

 


 

Stanford Medicine Resources:

Footer Links: